Trudeau Institute Fellow Dr. Stephen Thomas has been named lead principal investigator for Pfizer/BioNTech’s phase 3 clinical trial for a COVID-19 vaccine candidate.
On Monday, those companies announced early tests showing that the vaccine was more than 90 percent effective in preventing COVID-19.
Thomas, the chief of infectious disease for SUNY Upstate Medical University in Syracuse, became Trudeau’s first fellow in 2018. He has worked closely with the Institute on projects targeting Zika virus and other emerging infectious diseases and was co-organizer of the Institute’s 2018 Global Health Summit.
In his role as lead principal investigator, Thomas will assist Pfizer and BioNTech as the companies share trial results with regulatory agencies.